Elixinol signs binding term sheet to acquire Vitable
Elixinol Wellness (ASX: EXL) has signed a binding term sheet for the proposed acquisition of Vitable, a personalised supplement and subscription platform. The proposed transaction, which remains subject to conditions, shareholder approval, and confirmatory due diligence, is expected to create a combined Group with A$20m+ in revenue from completion.
On full realisation of the scrip-based earn-out terms, the combined business will target A$27m in revenue and approximately A$3m in EBITDA by 2028, representing a step change in scale for Elixinol shareholders.
Vitable’s model centres on a quiz-based personalisation engine that generates tailored daily supplement packs delivered via subscription. The platform currently serves 7,851 active subscribers and holds 1.84 million quiz and recommendation records, representing a substantial data asset the combined Group would inherit from day one.
When big ASX news breaks, our subscribers know first
What Vitable brings to the Elixinol portfolio
Elixinol’s existing brand portfolio spans everyday health food and functional supplements, but lacks a direct digital customer relationship with recurring subscription revenue. Vitable is proposed to fill that gap, adding a health technology platform to sit alongside the company’s established brands.
The combined portfolio, if the acquisition completes, would comprise three distinct pillars:
| Brand | Category | What it adds to the Group |
|---|---|---|
| Hemp Foods Australia + Mt Elephant | Everyday health food | Whole foods, fibre, protein and better-for-you pantry products |
| The Healthy Chef | Functional supplements | Collagen, protein, powders and targeted daily nutrition |
| Vitable | Health technology platform | Personalised tablets and capsules in simple daily packs |
The announcement notes that cross-sell works in both directions across consented customer audiences. Vitable’s 1.84 million quiz and recommendation records would enrich personalisation, retention, and cross-sell capability across the whole group, not just the Vitable subscriber base.
From retail and wholesale to owned, recurring, direct
A key aspect of the proposed acquisition is the structural shift it enables in how Elixinol reaches and retains customers. Rather than relying solely on retail and wholesale channels, the company would gain app, email, and subscription channels through Vitable, which management believes would reduce repeated customer acquisition spend.
Three strategic shifts the acquisition is positioned to enable:
- Owned route to market: App, email and subscription channels that reduce reliance on paid acquisition
- Customer insight that compounds: Each interaction improves relevance and informs Group-wide product and service decisions
- A ready audience for growth: New products, services, and bolt-on brands can reach existing customers faster
Understanding personalised supplement subscriptions — and why global capital is chasing them
Vitable’s current model operates as a three-step loop: a customer completes a health quiz, receives a tailored supplement recommendation, and receives a recurring daily pack. Elixinol plans to explore extending this model to include at-home biomarker testing through specialist partners, adding measured results to each customer’s existing profile. This planned next stage, which remains subject to partner, regulatory, and clinical review, would allow the platform to track how results change over time and refine subsequent recommendations accordingly.
The subscription and personalisation model creates compounding value because each customer interaction improves the relevance of the next recommendation. Recurring subscription revenue is also more predictable than one-time retail sales, a quality that major global acquirers are now pricing into transactions at scale.
Global capital has moved decisively into this category in 2026, with several large consumer and digital health groups committing significant sums to acquire brands that combine direct customer relationships with recurring revenue:
- P&G + Thorne (science-backed supplements and personalised health): US$3.8bn cash, announced August 2026
- Hims & Hers + Eucalyptus (Australian consumer health and subscription platform): up to US$1.15bn, completed June 2026
- Unilever + Grüns (fast-growing direct-to-consumer supplement brand): consideration undisclosed, completed June 2026
The disclosed value across the P&G and Hims & Hers transactions alone exceeds US$4.95bn. These precedents validate the category Elixinol is moving into, though EXL operates at a materially different scale to the buyers involved.
Deal structure, conditions, and the path to completion
The proposed acquisition is structured across three tranches of consideration, with the majority of payments deferred and tied to performance or market capitalisation milestones:
- Unconditional (A$1.25m): Paid across completion, six months, and twelve months. Time-based with no performance condition attached.
- Conditional (A$1.25m): Paid at twelve months and twenty-four months. Gated on Net Revenue and Direct EBITDA growth.
- Platform kicker (A$1.0m): Available for up to thirty-six months from completion, but triggered only if EXL’s market capitalisation exceeds A$20m.
The path to completion follows four steps: the binding term sheet was signed in September 2026, followed by confirmatory due diligence and a transition plan, a General Meeting for shareholder approvals, and then completion with a six-month transition period. Dates remain subject to change.
The Vitable acquisition follows Elixinol’s completed US business divestment in early September 2026, in which the company sold its US operations to Ananda Health for up to A$465,000 while retaining the Elixinol brand IP across all other territories.
CEO & Executive Director, Natalie Butler
The announcement does not include a direct quote from Natalie Butler available for reproduction.
Management’s three-to-five-year ambition
Management has outlined an illustrative A$50m ambition for the combined Group over a three-to-five-year horizon. This figure is explicitly described in the announcement as an illustrative ambition and is not guidance.
The starting point, if the acquisition completes, would be the A$20m+ combined Group revenue Elixinol projects from completion. Management’s ambition represents a targeted growth trajectory from that base, with Vitable’s personalisation engine, subscriber relationships, and data asset positioned as the platform for that expansion.
For investors exploring how Elixinol funded its path to this acquisition, our detailed coverage of Elixinol’s capital reset strategy explains the convertible note structure, SKU rationalisation program, and supply chain changes that underpinned the margin recovery preceding this transaction.
Don’t Miss the Next Consumer Health Breakout
Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.
